Cover Image
市場調查報告書

中國的Valsartan Hydrochlorothiazide市場分析

Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 297278
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Valsartan Hydrochlorothiazide市場分析 Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018
出版日期: 2014年03月10日 內容資訊: 英文 40 Pages
簡介

中國高血壓患者數快要超過3億人。Novartis佔中國的Valsartan Hydrochlorothiazide市場80%以上。中國的高血壓的發病率,由於生活水準的改善和生活方式的變化而年年增加。

本報告提供中國的Valsartan Hydrochlorothiazide市場相關調查分析、主要廠商的市場佔有率、醫院市場上的銷售價格、提供主要製造商簡介、市場預測等,為您概述為以下內容。

第1章 Valsartan Hydrochlorothiazide的相關概念

  • 開發過程與適應
  • 全球市場銷售情形

第2章 中國的Valsartan Hydrochlorothiazide的市場概要

  • 專利狀況
  • 主要製造商
  • 市場規模

第3章 中國的Valsartan Hydrochlorothiazide的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Valsartan Hydrochlorothiazide的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 各中國的Valsartan Hydrochlorothiazide(劑型)的市場規模分析

  • 各市場佔有率:銷售額、劑型
  • 各市場佔有率:銷售量、劑型

第6章 中國的醫院市場上Valsartan Hydrochlorothiazide的標準價格(各企業)

  • Novartis
  • Jiangsu Wangao Pharmaceutical Co., Ltd.
  • China Resources Saike Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Cisen Pharmaceutical Co., Ltd.
  • Conquer Pharmaceutical Co., Ltd.
  • Bailu Pharmaceutical Co., Ltd.
  • Changzhou Siyao Pharmaceutical Co., Ltd.

第7章 中國的Valsartan Hydrochlorothiazide市場上主要製造商分析

  • Novartis
  • Jiangsu Wangao Pharmaceutical Co., Ltd.
  • China Resources Saike Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Cisen Pharmaceutical Co., Ltd.

第8章 中國的Valsartan Hydrochlorothiazide市場概要

  • 高血壓的發病率預測
  • 市場規模的預測
  • 競爭格局的預測

圖表

目錄
Product Code: 1403133

According to WHO, one-third of the world's adults have hypertension. The global market value of antihypertensive drugs is tens of billion dollars.

Due to the long history of antihypertensive drugs, most hypertensive patients need 2 or more kinds of antihypertensive drugs to reduce the blood pressure to a normal level. There are more than 20 compound preparations of sartan drugs in global market. The first category is the compound preparation of sartan and diuretic hydrochlorothiazide. Because the compound of sartan drugs and diuretic has better effect than other medication compounds, most sartan and hydrochlorothiazide compound preparations are approved by FDA, including the compound preparation of diuretic chlorthalidone and azilsartan. The second category is the compound preparation of sartan and calcium antagonist. The third category is the direct renin inhibitor and sartan compound preparation. The fourth one is triplex compound preparation. Novartis developed valsartan compound preparation after valsartan was launched. In October 1997, the compound preparation of valsartan hydrochlorothiazide was successfully developed by Novartis and approved by FDA with the trade name "CoDiovan". Unlike valsartan, valsartan hydrochlorothiazide tablet can only treat hypertension instead of congestive heart failure and myocardial infarction.

Statistics shows that the number of hypertensive patients in China is higher than 260 million, which may even be more than 300 million. According to CRI, market value of hypertensive drugs in China exceeds CNY 40 billion every year. The CAGR of sales revenue of valsartan hydrochlorothiazide in Chinese sample hospitals surpassed 100% from 2007 to 2012. Based on the sales revenue, Novartis takes more than 80% of the valsartan hydrochlorothiazide market in China while the other market is seized by Chinese enterprises such as Jiangsu Wangao Pharmaceutical Co., Ltd.

It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard and changes of lifestyle. As Chinese people's incomes increase, the affordability of antihypertensive drugs increases. As a result, market size of Valsartan Hydrochlorothiazide in China will keep increasing in the next few years.

Through this report, the readers can acquire the following information:

  • Market Share of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market
  • Sales Value of Valsartan Hydrochlorothiazide in China Hospital Market
  • Major Valsartan Hydrochlorothiazide Manufacturers in China
  • Prospect of China Valsartan Hydrochlorothiazide Market

The following enterprises and people are recommended to purchase this report:

  • Antihypertensive APIs and Finished Product Manufacturers
  • Investors /Research Agencies Focusing on China Antihypertensive Drug Market

Table of Contents

1. Relevant Concepts of Valsartan Hydrochlorothiazide

  • 1.1. Development Process and Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Valsartan Hydrochlorothiazide in China, 2009-2013

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Valsartan Hydrochlorothiazide in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Valsartan Hydrochlorothiazide by Dosage Form in China, 2009-2013

  • 5.1. Market Size by Sales Value
  • 5.2. Market Size by Sales Volume

6. Reference Price of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market, 2014

  • 6.1. Novartis
  • 6.2. Jiangsu Wangao Pharmaceutical Co., Ltd.
  • 6.3. China Resources Saike Pharmaceutical Co., Ltd.
  • 6.4. Lunan Better Pharmaceutical Co., Ltd.
  • 6.5. Cisen Pharmaceutical Co., Ltd.
  • 6.6. Conquer Pharmaceutical Co., Ltd.
  • 6.7. Bailu Pharmaceutical Co., Ltd.
  • 6.8. Changzhou Siyao Pharmaceutical Co., Ltd.

7. Analysis on Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2014

  • 7.1. Novartis
  • 7.2. Jiangsu Wangao Pharmaceutical Co., Ltd.
  • 7.3. China Resources Saike Pharmaceutical Co., Ltd.
  • 7.4. Lunan Better Pharmaceutical Co., Ltd.
  • 7.5. Cisen Pharmaceutical Co., Ltd.

8. Market Overview of Valsartan Hydrochlorothiazide in China, 2014-2018

  • 8.1. Forecast on Incidence of Hypertension
  • 8.2. Forecast on Market Size
  • 8.3. Forecast on Competition Pattern

Selected Charts

  • Chart Valsartan Hydrochlorothiazide Products Approved to Market in China by 2014
  • Chart Sales Value of Valsartan Hydrochlorothiazide in Global Market, 2009-2013
  • Chart Sales Value of Valsartan Hydrochlorothiazide in China Hospital Market, 2009-2013
  • Chart Market Share of Valsartan Hydrochlorothiazide Enterprises by Sales Value in China, 2009-2013
  • Chart Price of Valsartan Hydrochlorothiazide Produced by Novartis in China Hospital Market, 2014
  • Chart Price of Valsartan Hydrochlorothiazide Produced by Jiangsu Wangao Pharmaceutical Co., Ltd. in China Hospital Market, 2014
  • Chart Forecast on Market Size of Hospital-use Valsartan Hydrochlorothiazide in China, 2014-2018
Back to Top